Tempest Expands Portfolio with Strategic Acquisition of Dual-Targeting CAR-T Assets, Extends Runway to Mid-2027

Tempest Therapeutics has closed a strategic acquisition of dual-targeting CAR-T assets, extending its operational runway to mid-2027. The acquisition includes a clinical-stage dual-targeting CD-19/BCMA CAR-T, TPST-2003, with a planned BLA filing in China for 2027. Matt Angel, Ph.D., joins Tempest as President and CEO, and the company plans to pursue business development discussions to advance pivotal development of Amezalpat (TPST-1120) in first-line liver cancer.